Objective-Atherosclerotic lesions are associated with the accumulation of reactive aldehydes derived from oxidized lipids.
I t is currently believed that during atherogenesis, arterial lesions develop in response to cumulative injury caused by the retention of lipoproteins within the vessel wall. 1 Although specific mechanisms underlying the formation of atherosclerotic lesions remain unclear, it has been suggested that enzymatic and nonenzymatic oxidation of lipoproteins generates immunogenic products that attract leukocytes to the vessel wall. [2] [3] [4] Phagocytosis of oxidized lipids by macrophages results in the formation of foam cells that give rise to advanced lesions. In agreement with this view, it has been found that products of oxidized lipoproteins accumulate in the atherosclerotic lesions of humans and atherosclerosisprone animals, and that the levels of oxidized lipoproteins in plasma and atherosclerotic lesions are strongly associated with coronary artery disease in human. [5] [6] [7] [8] Assessments of the contribution of oxidized lipids to atherogenesis in genetically altered mice have shown that deletion of the lipid-oxidizing enzyme 12/15 lipoxygenase 9 decreases atherosclerotic lesion formation. Conversely, deletion of enzymes that promote the removal of lipid peroxidation products, such as paraoxonase, platelet activating factor-acetylhydrolase, 10 and aldose reductase, 11 increases atherogenesis. In addition, some studies suggest that deletion of macrophage receptors that mediate the uptake of oxidized, but not nonoxidized, lipoprotein (eg, CD36) prevents lesion formation. 12 However, the role of these receptors and 12/15 lipoxygenase in atherogenesis remains controversial because other studies have shown that transgenic overexpression of 12/15 lipoxygenase prevents atherosclerotic lesion formation, 13 and deletion of CD36 does not diminish atherosclerosis in apolipoprotein E (apoE)-null mice. 14 Although such conflicting results could be attributable to complex gene-diet interactions 15 and compensatory changes in gene expression, 16 a cause-and-effect relationship, if any, between oxidized lipids and atherogenesis has not been established. Attempts to prevent atherosclerosis by antioxidants, such as vitamin E, vitamin C, and β-carotene, have yielded mixed results in animal models and universally negative results in clinical trials. 17, 18 Inhibition of lipid oxidation at the site of lesion formation is intrinsically problematic. Lipid peroxidation is propagated by highly reactive free radicals that are difficult to quench. Although naturally occurring antioxidants, such as vitamin E, efficiently remove secondary free radicals, they do not prevent the initiation of lipid peroxidation by adventitious metal ions. Moreover, for continued quenching, vitamin E and C require recycling by cell constituents, such as reduced glutathione, which are not present in the subintimal space, where most oxidized lipids accumulate. Antioxidant enzymes that detoxify free radicals and oxidants in cells are also not present in this acellular milieu. Furthermore, even in the presence of antioxidants, free radicals that escape quenching generate a host of secondary products that amplify and prolong oxidative injury. Therefore, to be effective, an ideal antioxidant should prevent the initiation of autocatalytic lipid peroxidation reactions and safely remove secondary products of oxidation without the need for metabolic recycling.
Although most protein antioxidants are enzymes that remove specific reactive oxygen species, dipeptides containing histidine are evolutionarily conserved general antioxidants that can prevent the initiation of lipid peroxidation by chelating metals and quenching reactive species. These naturally occurring dipeptides include carnosine (β-alanylhistidine), homocarnosine (γ-amino-butyric acid-histidine), anserine (β-alanyl-L1-methylhistidine), balenine (β-alanyl-L3-methylhistidine), and their N-acetylated forms. 19 In mammals, carnosine is the most abundant and is present in high concentrations in the skeletal muscle, heart, and brain. 20, 21 Particularly high concentrations of carnosine (5-20 mmol/L) are synthesized in the skeletal muscle, where it is believed to facilitate glycolysis by buffering lactic acid during periods of high-metabolic activity. 22, 23 Carnosine also quenches singlet oxygen and chelates metals, and it has also been shown to form stable adducts with some reactive carbonyl species generated in oxidized lipids. 24, 25 As a result, it could prevent the initiation of lipid oxidation and facilitate the removal of secondary toxic products. The current study was, therefore, designed to examine whether these peptides can inhibit lowdensity lipoprotein (LDL) oxidation and inactivate lipid peroxidation products and by doing so decrease atherosclerotic lesion formation in mice. Preliminary results of this study have been previously reported in an abstract form. 26 
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Histidine Dipeptides Protect LDL From Oxidation
To determine the effects of histidine dipeptides on processes that contribute to atherosclerosis, we first examined whether these peptides inhibit LDL oxidation. Although carnosine is synthesized in cells, it is also present in the plasma [27] [28] [29] as a result of dietary ingestion and interorgan transport. Hence, to study how carnosine affects LDL oxidation, which is believed to be an extracellular event, LDL was oxidized by copper in the presence of the dipeptides. The extent of LDL oxidation was estimated by measuring thiobarbituric acid reactive substances (TBARS). We found that the addition of 10 mmol/L carnosine decreased LDL oxidation by ≈90%. Anserine was moderately effective (≈30% inhibition), whereas homocarnosine led to a small (≈35%), but statistically significant increase in LDL oxidation ( Figure 1A ). Thus, among the dipeptides tested, carnosine was the strongest inhibitor of LDL oxidation. In addition, carnosine was also effective in preventing LDL oxidation by bone marrow-derived macrophages (BMM). At a concentration of 1 mmol/L, carnosine inhibited BMMmediated LDL oxidation by ≈40%, whereas at 10 mmol/L, it completely prevented LDL oxidation ( Figure 1B) . Moreover, preincubation of BMM with a membrane-permeable analog of carnosine, N-acetyl-carnosine, also significantly reduced LDL oxidation, suggesting that carnosine inhibits LDL oxidation by both extracellular and intracellular mechanisms. Taken together, these observations indicate that carnosine prevents nonenzymatic as well as cell-mediated LDL oxidation as measured by the formation of TBARS.
Although measurements of TBARS reflected the generation of lipid-derived carbonyls, these assays provided no information regarding the specific intermediates or end products of lipid oxidation that might be affected by carnosine. Hence, we measured the accumulation of lipid hydroperoxides, generated from peroxyl radicals, conjugated dienes formed by fatty acid fragmentation and free aldehydes malondialdehyde (MDA) and 4-hydroxynonenal (HNE), which are the major end products of lipid peroxidation. As shown in Figure 1C , similar to TBARS, carnosine prevented the formation of both lipid hydroperoxides and conjugated dienes in Cu 2+ -oxidized LDL (oxLDL). However, at a concentration of 10 mmol/L, carnosine inhibited the TBARS formation by ≈90%, whereas lipid hydroperoxides and conjugated diene formation were prevented by 60% to 70%, indicating that carnosine was more effective in preventing the formation of TBARS than hydroperoxides and conjugated dienes. Direct measurements of HNE and MDA by gas chromatography/mass spectrometry showed that carnosine strongly decreased the abundance of these aldehydes in oxLDL ( Figure 1D ). Collectively, these observations suggest that carnosine prevents the initiation of lipid peroxidation, presumably by chelating copper, and that it removes free aldehydes once they are generated.
Chemical Reactivity of Histidine Dipeptides With Unsaturated Aldehydes
Carnosine can prevent the appearance of lipid-derived free aldehydes, such as MDA or HNE, by either preventing their formation or by reacting with them once they are formed. To distinguish between these possibilities, we measured the reactivity of carnosine with free aldehydes directly. When we incubated carnosine with the lipid-derived unsaturated aldehydes-acrolein, 4-hydroxyhexenal (HHE), octenal, HNE, and 4-oxononenal (ONE)-we found that in each case, there was a time-dependent decrease in the concentration of the free aldehyde. The progression of the reaction of carnosine with HNE and HHE is shown in Figure 2A and 2B). The rate of aldehyde loss was best described by a single exponential: A t =A 0 e −k obs t ; where A t is the concentration of aldehyde at time t, A 0 is the initial aldehyde concentration, and k obs is the apparent rate constant of the reaction. Using this equation, k obs values were calculated at several different concentrations of histidyl dipeptides. The values of k obs displayed a linear dependence on dipeptide concentration ( Figure 2C) , with a slope equal to the second order rate constant. Such second order rate constants were calculated for the reaction of acrolein and HNE with several histidyl dipeptides. These are listed in the Table. As shown, we found that all dipeptides that we tested reacted with the aldehydes faster than histidine. The highest rate was observed with anserine, although the reaction of anserine with HNE did not reach completion. The plot of k obs versus anserine concentration had a large intercept indicating the formation of dissociable complex with K eq =0.71±0.03 mmol/L that did not lead to the formation of a stable complex. Collectively, these data show that of the series tested, carnosine displayed the most efficient and the most complete reaction with both HNE and acrolein and was therefore used in all subsequent experiments.
Lipid peroxidation generates several aldehydes of diverse structure and variable reactivity. Thus to ensure that the reactivity of carnosine was not limited to only HNE or acrolein, we measured the rate of reaction of carnosine with other alkenals. Second order rate constants of the reaction of carnosine with acrolein, HHE, octenal, HNE, and ONE are listed in the Table. The values of these constants indicate that carnosine reacts with acrolein at a rate 10× faster than any other aldehyde, whereas it reacts with equal avidity with HNE, HHE, octenal, and ONE. The reaction with MDA was inefficient; only 27.5% of MDA was conjugated after 3 days of incubation with 50 mmol/L carnosine. Chemical identities of carnosine-aldehyde conjugates were established by electrospray ionization + -mass 
Formation of Carnosine-Aldehyde Conjugates in oxLDL
To examine whether in addition to free aldehydes, carnosine also reacts with aldehydes in oxLDL, LDL was oxidized with Cu 2+ in the presence of carnosine, and carnosine-aldehyde conjugates were resolved by reverse phase high performance liquid chromatography and analyzed online by ESI + -MS. Non-oxLDL incubated with carnosine served as control. As shown in Figure Table II in the online-only Data Supplement). Fragmentation patterns of oxLDL-derived carnosine-aldehyde conjugates were in agreement with reagent standards.
Carnosine Protects Macrophages From HNE-Induced Apoptosis
Having found that carnosine reacts with most, if not all, the unsaturated aldehydes generated during lipid peroxidation, we next assessed the biological significance of these reactions by testing whether carnosine decreases biological toxicity of these aldehydes. We found that although incubation of BMM in Hanks' balanced salt solution with HNE induced apoptotic cell death, the carnosine-HNE conjugate was not toxic ( Figure  3A) . These data indicate that conjugation with carnosine significantly diminishes the cytotoxicity of HNE. We also found that BMM preloaded with 2 different cell-permeable analogs of carnosine were more resistant to HNE-induced apoptosis than naïve cells in Hanks' balanced salt solution ( Figure  3B ). Preincubation with carnosine itself also led to a small decrease in HNE-induced cell death, but the decrease was statistically insignificant presumably because of poor permeability. 
3C
). These observations suggest that carnosine prevents HNE toxicity even in the presence of plasma proteins and are consistent with previous observations showing that carnosine prevents glomerular cell death in vivo. 30 Taken together, these observations indicate that carnosine can form conjugates with HNE and, therefore, could prevent the toxicity of HNE and related aldehydes.
Carnosine Feeding Diminishes Atherogenesis
Given our observations that carnosine prevents LDL oxidation, decreases the toxicity of lipid-derived aldehydes, and protects cells from aldehyde toxicity, we tested whether treatment with carnosine will prevent atherosclerotic lesions formation. For these experiments, we treated apoE-null mice with a readily bioavailable analog of carnosine, ODC, by putting it in their drinking water for 6 weeks. In most mammals, carnosine is cleaved in the plasma by carnosinase; however, because the peptidyl bond in ODC is in the D-rather than L-conformation, this compound is protected from cleavage. Moreover, the use of a cell-permeable ester, which has been shown to improve bioavailability of highly hydrophilic compounds, such as D-carnosine, 31, 32 was used to optimize intestinal absorption. The ester is then readily hydrolyzed by tissue or plasma esterases 32, 33 generating free carnosine in the plasma. Addition of ODC to the drinking water led to a 13-fold increase in plasma carnosine concentration in these mice (0.04±0.03 µmol/L versus 0.52±0.14 µmol/L; Figure 4Ai ) and 2-to 2.5-fold increase in the carnosine content in spleen and aorta (Figure 4Aii and 4Aiii). Drinking water containing ODC did not affect body weight or plasma cholesterol levels (503±38 mg/dL control versus 524±30 ODC-fed); however, morphometric analysis of aortic valves recovered from these mice showed that the ODC-treated mice had significantly smaller lesions than untreated mice ( Figure 4B ). Staining of the aortic valve with anti-CD68 antibody showed a significant decrease in the macrophage content in the lesions of ODC-fed mice as compared with water-fed controls ( Figure 4C ). Because we found that carnosine reacts with lipid-derived aldehydes, we expected to see a significant reduction in aldehyde accumulation in the atherosclerotic lesions of ODC-treated mice. Indeed, our measurements of the protein-adducts of acrolein, HHE and HNE, indicated a consistent and robust (70%-80%) decrease in the abundance of these adducts in the atherosclerotic lesions of ODC-treated mice ( Figure 5A-5C ). Taken together, these observations indicate that oral intake of ODC prevents the accumulation of protein-aldehyde adducts and macrophages in atherosclerotic lesions, and that these changes are accompanied by a decrease in lesion size. 
Carnosine-Aldehyde Conjugates in the Urine
The decrease in atherosclerotic lesion in apoE-null mice could be attributable to inhibition of LDL oxidation in the arterial wall. Additionally, as indicated by our preceding experiments, carnosine could also react with lipid oxidation-derived aldehydes and remove them from the lesion. Therefore, we reasoned that if carnosine is removing aldehydes from the lesion, the carnosine-aldehyde conjugates should appear in the urine. To test this possibility, carnosinealdehyde adducts in urine were quantified by the sensitive multiple reaction monitoring technique ( Figure IV in the online-only Data Supplement). High levels of carnosine-HNE and carnosine-HHE were observed in the urine of apoE-null mice that were treated with ODC for 6 weeks ( Figure 5D ) and in which lesion size was decreased. To test whether the urinary levels of the conjugate are associated with lesion formation, we placed wild-type (WT) and apoE-null mice on ODC, and measured abundance of carnosine-aldehyde conjugates in the urine. We found that ODC delivered in drinking water appeared in the urine of the mice not only as a free peptide, but also as carnosine-aldehyde conjugates, particularly carnosine-HHE ( Figure 5E ). Significantly, the level of this conjugate was much higher in the urine of ODC-treated apoE-null than WT mice, indicating that apoE-null mice generate higher levels of lipid peroxidation aldehydes than WT mice, and that these aldehydes are captured by carnosine and removed in the urine.
Discussion
The major findings of this study are that the endogenous histidyl dipeptide carnosine reacts with a wide range of aldehydes produced by lipid oxidation. Carnosine prevents LDL oxidation and forms stable covalent conjugates with aldehydes generated during LDL oxidation. We also found that carnosine decreases the cytotoxicity of lipid-derived aldehydes and that dietary intake of carnosine prevents early atherosclerotic lesion formation in apoE-null mice. This decrease in atherogenesis was accompanied by decreased accumulation of aldehydemodified proteins in the lesions and increased appearance of carnosine-aldehyde conjugates in the urine. Taken together, these findings support the notion that dietary intake of carnosine could decrease the formation of atherosclerotic plaques. Carnosine is an endogenous histidyl dipeptide. In tissues with high-metabolic activity, skeletal muscle, heart, and brain, carnosine is synthesized from β-alanine and histidine by carnosine synthase. 34, 35 It is also a dietary constituent present in particularly high amounts in meat. 36 High levels (10-20 mmol/L) of carnosine in anaerobic white skeletal muscle of birds, horses, and pigs are consistent with the view that carnosine prevents tissue acidification by buffering intracellular pH during high-glycolytic activity. 37, 38 However, carnosine contains highly reactive nucleophilic amines, which are well suited to form covalent conjugates with aldehydes, such as those generated in oxidized lipids. Indeed, studies from our laboratory ( Figure 2 ) and others 24, 25 show that carnosine reacts avidly with several lipid-derived aldehydes. Although these aldehydes can also react with reduced glutathione at much higher rates 39, 40 that are further accelerated by glutathione S-transferases, 41, 42 their reaction with carnosine may be a second line of defense under conditions when glutathione is depleted. This is consistent with our observation that increasing intracellular carnosine content prevented HNE toxicity, suggesting that despite its slow reactivity, carnosine offers significant protection against aldehyde toxicity even in glutathione replete cells, and that aldehyde detoxification may be a significant function of endogenous carnosine and related histidyl dipeptides.
The role of carnosine as an aldehyde quencher is supported by our data showing that incubation with carnosine prevented LDL oxidation. At high concentrations (10 mmol/L), carnosine decreased aldehyde generation, without the formation of carnosine-aldehyde conjugates, indicating that at these concentrations carnosine prevents LDL oxidation, presumably by chelating copper. Histidine and histidine containing peptides chelate metals and therefore are quite efficient at preventing free radical generation and lipid peroxidation. 43 However, at low concentrations (1 mmol/L), carnosine did not completely prevent lipid oxidation but formed covalent conjugates with aldehydes generated in oxidized lipid. Collectively, these data suggest that carnosine is more efficient at quenching aldehydes than chelating metals and that at physiological levels in tissues other than skeletal muscle (<1 mmol/L), the aldehyde-quenching effects of carnosine are likely to be more pronounced than its metal chelating abilities. Thus, the decrease in atherosclerotic lesion at a steady-state plasma concentration of 0.5 to 0.6 μmol/L carnosine could be attributed to aldehyde quenching rather than metal chelation.
That carnosine prevents atherogenesis by removing lipid peroxidation-derived aldehydes is further supported by our data showing that oral intake of ODC led to the appearance of HHE and HNE conjugates of carnosine in the urine. These observations suggest that carnosine protects against atherosclerosis by removing reactive aldehydes from the lesions. This view is further supported by the observation that the abundance of protein-aldehyde adducts in the lesions was reduced in the carnosine-fed apoE-null mice. These findings imply that aldehydes, such as HHE and HNE, are significant contributors to atherosclerotic lesion formation. Aldehydes, such as HNE and ONE, are generated from the oxidation of n-6 polyunsaturated fatty acids (PUFA) and the rate of production of these aldehydes depends on cell-specific expression of 15-or 12-lipoxygenase. [44] [45] [46] HHE, on the contrary, is derived from the oxidation of n-3 PUFAs (α-linolenic acid, eicosapentanoic acid, and docosahexanoic acid), and it is generated in humans and rodents at higher concentration than HNE. [47] [48] [49] In the present study, we found carnosine-HHE conjugates in WT and ApoE-null mice on a normal chow after a single dose of ODC; however, carnosine-HNE was detected only in mice receiving a high-fat diet, suggesting that HHE is the major aldehyde formed during low levels of lipid peroxidation. Moreover, our data showing that HHE is the predominant aldehyde-carnosine conjugate in the urine of ODC-treated apoE-null mice and that its levels in apoE-null mice are higher than in WT mice indicate that n-3 PUFA are likely to be more readily oxidized in atherosclerotic lesions than n-6 PUFA. However, further experiments are required to examine the differential oxidation of n-3 and n-6 PUFAs and the contribution of their products to atherogenesis.
Our observations that dietary carnosine supplementation prevents atherosclerosis lesion formation in apoE-null mice are consistent with the recent work published by Menini et al, 50 who also report that treatment with carnosine prevents atherosclerotic lesion formation. Such concordance of results obtained in 2 different laboratories strengthens the validity of the observation that carnosine decreases atherosclerosis. Moreover, in addition to revealing the antiatherogenic role of carnosine, our findings provide a more comprehensive and mechanistic basis of carnosine action by showing that histidyl peptides react directly with lipid peroxidation-derived aldehydes and that carnosine prevents LDL oxidation, aldehyde generation, and oxLDL-induced macrophage apoptosis. Collectively, these observations and those of Menini et al 50 strengthen the rationale for studying the role of endogenous carnosine in atherosclerosis and for testing whether carnosine supplementation in diet could prevent or diminish atherosclerosis in humans. Carnosine is a natural dipeptide, which is present in high concentration in chicken, turkey, and beef 36, 51 and, therefore, further studies could be designed to determine whether increased consumption of such foods could help prevent or retard atherosclerotic lesion formation. Finally, a decrease in atherosclerosis by carnosine feeding reinforces the view that reactive products of lipid peroxidation play a pivotal role in atherosclerosis.
This study shows that carnosine, a natural dipeptide, prevents low-density lipoprotein oxidation as well as the cytotoxic effects of reactive aldehydes generated by lipid oxidation. We report that dietary intake of carnosine decreases atherosclerotic lesion formation in mice. These findings suggest that treatment with carnosine or related peptides may be a useful therapy for preventing and decreasing atherosclerotic lesion formation. Carnosine is a dietary supplement, and it is well tolerated even at high doses; therefore, its antiatherogenic effects could be readily tested in humans. Clinical evaluation of carnosine and related peptides could potentially lead to the development of a novel, peptide-based therapy for prevention, treatment, and management of atherosclerotic disease. Despite extensive investigation, the role of low-density lipoprotein oxidation in atherogenesis remains unclear. Our studies showing that treatment with carnosine, which prevents low-density lipoprotein oxidation and the cytotoxic effects of lipid peroxidation products, decreases atherosclerosis support the view that oxidation of low-density lipoprotein and the generation of lipid peroxidation products are important events that contribute to the formation of atherosclerotic lesions.
Significance
